Novo Nordisk Denmark A/S

CVR: 38180045

Growing 38% p.a.Large companyEstablished (9 yrs)Profitable

Secondary names: Novo Nordisk Region Europe Pharmaceuticals A/S, Novo Nordisk North West Europe Pharmaceuticals A/S

Previous names: Novo Nordisk Region Europe Pharmaceuticals A/S

Active

Novo Nordisk Denmark A/S demonstrates a strong financial trajectory with significant revenue growth, increasing from 509.9 million DKK in 2022 to 2.37 billion DKK in 2024, reflecting a robust annual growth rate. Profitability has also improved, with profits rising from 33.5 million DKK in 2022 to 86.1 million DKK in 2024, indicating effective cost management and operational efficiency. The company's equity position has strengthened, growing from 49.1 million DKK in 2022 to 101.8 million DKK in 2024, which enhances its financial stability. Overall, Novo Nordisk is well-positioned within the pharmaceutical wholesale industry, showcasing resilience and a positive outlook for continued growth.

AI-generated summary

Overview

Company type: A/S; Aktieselskab
Address: Kay Fiskers Plads 10, 2300 København S; KØBENHAVN; 2300 København S; Find nearby companies
Founded: 14.11.2016

Details

Industry: Engroshandel med medicinalvarer og sygeplejeartikler; Code: 464610
Employees: 81 employees; 76 FTE; (2018)
Capital: 500.000 kr.

Contact

Advertising protected

Purpose

Selskabets formål er at markedsføre, promovere, importere, sælge og distribuere farmaceutiske og medicinske produkter, repræsentation af selskaber, supporterende services og forretningsassistance til interessenter i Europa, rådgivning og services i forbindelse med registrering af farmaceutiske produkter, forskning og udvikling af farmaceutiske produkter, kliniske forsøg, samt anden hertil knyttet virksomhed der ikke er forbudt ved lov. Selskabets formål er tillige at understøtte Novo Nordisk A/S farmaceutiske aktivitet. Selskabet tilstræber at drive sin virksomhed på økonomisk, miljømæssigt og socialt ansvarlig vis.